Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Mirum Pharmaceuticals announced a leadership transition, with Dr. Quan departing and being thanked for her contributions. The company positions itself as a rare disease specialist with a clinical pipeline including volixibat for PSC/PBC, brelovitug for chronic hepatitis delta virus, zilurgisertib for FOP, and MRM-3379 for Fragile X syndrome.